New Antibody-Drug Conjugate Shows Effectiveness Against Acute Lymphoblastic Leukemia

A targeted antibody-drug conjugate has been found to effectively eliminate measurable residual disease in adult acute lymphoblastic leukemia, thereby cutting relapse risk and extending long-term survival.